THE LACK OF CORRELATION BETWEEN TP53 MUTATIONS AND GASTRIC CANCER: A REPORT FROM A PROVINCE OF IRAN by Saffari-Chaleshtori, Javad. et al.
  ___________________________  
Corresponding author: Morteza Hashemzadeh-Chaleshtori, Cellular and Molecular Research 
Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Rahmatieh, 
Shahrekord, Iran, Postal code: 8813833435, Tel: +98-38-33346692. Fax: +98-38-33330709. E-
mail: molecularskums@gmail.com 
 
 
 
 
 
 
UDC 575 
                https://doi.org/10.2298/GENSR1701235S 
                               Original scientific paper 
 
 
 
THE LACK OF CORRELATION BETWEEN TP53 MUTATIONS AND GASTRIC 
CANCER: A REPORT FROM A PROVINCE OF IRAN 
 
Javad SAFFARI-CHALESHTORI1, Mohammad-Amin TABATABAIEFAR2,  
Payam GHASEMI-DEHKORDI3, Effat FAROKHI3, Mohammad-Taghi MORADI3,  
Morteza HASHEMZADEH-CHALESHTORI3 
 
1 Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord 
University of Medical Sciences, Shahrekord, Iran 
2 Department of Medical Genetics, School of Medicine, Isfahan University of Medical 
Sciences, Isfahan, Iran 
3 Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord 
University of Medical Sciences, Shahrekord, Iran 
 
 
Saffari-Chaleshtori J., M.-A. Tabatabaiefar, P. Ghasemi-Dehkordi, E. Farokhi, M.-T. 
Moradi, M. Hashemzadeh-Chaleshtori (2017): The lack of correlation between TP53 
mutations and gastric cancer: a report from a province of Iran.- Genetika Vol49, No1, 
235-246. 
Gastric cancer ranks second cause of cancer death worldwide after lung cancer. Its 
etiology is heterogeneous and genetic factors including protooncogenes and tumor 
suppressor genes always contribute to the progression of cancer. The TP53 tumor 
suppressor gene has a broad role in genomic stability and DNA repair. The aim of this 
study was to determine the TP53 gene mutations in gastric cancer specimens in 
Chaharmahal Va Bakhtiari province of Iran. In this descriptive-lab based study, we 
investigated the promoter and exons of TP53 gene mutations in 38 paraffin-embedded 
gastric cancer specimens. DNA was extracted following a standard phenol-chloroform 
protocol. The TP53 gene mutations were determined using PCR-SSCP & PCR-RFLP 
procedures. The present study revealed no TP53 gene mutation in the promoter and 
exons in the gastric cancer subjects studied. While TP53 gene mutations have been 
reported as the most frequent genetic alterations and are found in about 50% of the 
human malignancies, no mutation was detected in this study. This may be due to 
mutations in other related genes in the same pathway or epigenetic factors. 
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INTRODUCTION 
 Gastric cancer is the main cause of cancer death worldwide (HOWSON et al., 1986). Gastric 
cancer comprises the second most frequent cancer worldwide and the fourth in Europe 
(GONZALEZ et al., 2002). The two type of gastric cancer include the intestinal and peripheral, or 
the so-called intestinal, types (LAUREN, 1965; KATIYAR et al., 2000). Although environmental 
factors such as Helicobacter pylori (H. pylori) infections are considered to be of importance for 
the familial clustering of gastric carcinoma (HEMMINKI and JIANG, 2002), gastric cancer is 
complex in nature and could involve many genes and their interaction with environmental factors. 
Proto-oncogenes and Tumor suppressor genes such as TP53 are important in carcinogenesis (CHO 
et al., 2005). 
 The transcription factor p53 responds to diverse cellular stresses to regulate target genes 
that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. P53 
appears to induce apoptosis through non-transcriptional cytoplasmic processes (TOLEDO et al., 
2006). P53 has an important role in transcriptional regulation and cytoplasmic functions (GREEN 
and KROEMER, 2009). This gene is involved in cell cycle control (QIAN et al., 2008) and acts to 
decrease the angiogenesis (SANO et al., 2007). Alteration or inactivation of TP53, the gene 
encoding p53, by mutation or by interaction with oncogene products of DNA tumor viruses can 
lead to cancer (LEVINE et al., 1991). Post translation processes such as acetylation (TANG et al., 
2008), phosphorylation (TAIRA et al., 2007) and methylation (SHI et al., 2007) regulate p53 
function. P53 limits malignant progression by suppressing the acquisition of further alterations 
that lead to tumor progression (FELDSER et al., 2010).TP53 is on the short arm of chromosome 17 
(BENCHIMOL et al., 1985). It contains 11 exons, 2 transcriptional start sites in exon 1, and 
alternative splicing sites in intron 2 and between exons 9 and 10 and transcription initiation site in 
intron 4 (BOURDON et al., 2005). There are two promoters in the TP53 gene. The first one is 
located 100 to 250 bp upstream of the non-coding first exon, and the second, a stronger promoter, 
is located within the first intron (REISMAN et al., 1988). Exon 1 and a part of the end exon 11 are 
non-coding but other regions are codings (TOMMASI et al., 2001). The hotspot regions of TP53 are 
in 5-8 exons and more than 90% of mutations are in three exons. This region encompasses codons 
110 to 307 (KATIYAR et al., 2000; TOMMASI et al., 2001). 
 So far, there have been many studies confirming a role for p53 in the carcinogenesis of 
gastric cancer. There are, however, other studies which fail to confirm such relation.  
 In the present study, PCR-Restriction Fragment Length Polymorphism (PCR-RFLP) 
technique was applied to detect two “hot spot” sites within exons 6 and 8 previously associated 
with gastric cancer. We also used polymerase chain reaction (PCR)-single stranded conformation 
polymorphism (SSCP) to rapid and sensitive detection of other mutations of TP53 gene in the 
promoter and exons 2 – 11 of the TP53 gene. 
 
MATERIALS AND METHODS 
Sampling and DNA extraction 
 The study was approved by the Review Board of Shahrekord University of Medical 
Sciences. Thirty-eight samples of paraffin-embedded gastric cancer archive tissues held in the 
central lab of Shahrekord University affiliated hospital (Kashani hospital) that collected from 
Chaharmahal Va Bakhtiari province of Iran, were recruited in this study (Figure 1). The average 
age of patients was about 67 years old. Thirty patients were male (51-77 years of age) and the rest 
were female (38-70 years of age). Totally, nine samples were diffuse and 29 were intestinal types 
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as well as 24, 8 and 6 of patients were in primary, advanced, and localization status of cancer. The 
patients’ groups were homogenous and all samples were collected at the time of diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The geographical position of Chaharmahal Va Bakhtiari province (southwestern Iran) that this 
study performed. 
 
  
 For DNA extraction, 25 mg of samples were deparaffined with Xylol & Ethanol and a 
standard phenol-chloroforms method was used. DNA concentration and purity was measured by 
spectroscopy (UNICO 2100, USA) (GRIMBERG et al., 1989). 
 
 
PCR amplification 
 PCR primers were designed using a primer 3 website (http://frodo.wi.mit.edu/ ) (Table 1). 
The promoter and exons 2 to 11 of the TP53 gene were amplified by PCR.  
The PCR amplification was performed in a total volume of 25 µL mixture containing: 100 ng 
genomic DNA, 1.0 µM of each primer, 200 µM of each dNTP, 2.0 µM of MgCl2 and 1.0 U Taq 
DNA polymerase and 10 µL Taq buffer (Fermentas, Germany) using the Astec gradient 96 
Thermocycler (Astec, Japan). 
 The thermal cycle profile was as follows: initial denaturation at 95°C for 3 min, followed 
by 36 cycles including: 95°C  for 1 min, annealing temperature for 30 sec for different primers 
(55ºC - 63ºC) and extension at 72°C for 30 sec (Table 2). A final extension step was followed at 
72°C for 8 min. All of the PCR products were analyzed on 8% poly acrylamide gel 
electrophoresis (PAGE). PCR products were visualized by means of silver (AgNo3) staining.  
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Table 1. PCR primers of p53 designed in this study 
Primers 
name 
Primers Sequence Tm Product length (bp) 
Ppro-F 
Ppro-R 
Pprom 
5´-TCTGGGAGAAAACGTTAGGG-3´ 
5´-CTGGCACAAAGCTGGACAGT-3´ 
5´-TCTGGGAGAAAACGTTT٭GGG-3´ 
57.3 
59.4 
57.3 
 
345 
P2-F 
P2-R 
P2m 
5´-ATCCCCACTTTTCCTCTTGC-3´ 
5´-TCCCACAGGTCTCTGCTAGG-3´ 
5´-ATCCCCACTTTTCCTT٭TTGC-3´ 
57.3 
61.4 
55.3 
 
198 
P3-F 
P3-R 
P3m 
5´-CCATGGGACTGACTTTCTGC-3´ 
5´-GGGGACTGTAGATGGGTGAA-3´ 
5´-CCATGGGACTGACTTC٭CTGC-3´ 
59.4 
59.4 
61.4 
 
170 
P4-F 
P4-R 
P4m 
5´-CCTGGTCCTCTGACTGCTCT -3´ 
5´-GCCAGGCATTGAAGTCTCAT-3´ 
5´-CCTGGTCCTCTGAT٭TGCTCT-3´ 
61.4 
57.3 
59.4 
 
360 
P5-F 
P5-R 
P5m 
5´-GACTTTCAACTCTGTCTCCT-3´ 
5´-CTGGGGACCCTGGGCAACCA-3´ 
5´-GACTTTCAACTCTGTT٭TCCT-3´ 
55.3 
65.5 
53.2 
 
270 
P6-F 
P6-R 
P6m 
5´-GTCCCCAGGCCTCTGATTC-3´ 
5´-CTTAACCCCTCCTCCCAGAG-3´ 
5´-GTCCCCAGGCCTCTA٭ATTC-3´ 
61 
61.4 
58.8 
 
190 
P7-F 
P7-R 
P7m 
5´-TTATCTCCTAGGTTGGCTCT-3´ 
5´-CAAGTGGCTCCTGACCTGGA-3´ 
5´-TTATCTCCTAGGTTA٭GCTCT -3´ 
55.3 
61.4 
53.3 
 
136 
P8-F 
P8-R 
P8m 
5´-CCTTACTGCCTCTTGCTTC-3´ 
5´-TGAATCTGAGGCATAACTGC-3´ 
5´-CCTTACTGCCTCTC٭GCTTC-3´ 
56.7 
55.3 
58.8 
 
240 
P9-F 
P9-R 
P9m 
5´-TTGCCTCTTTCCTAGCACTG-3´ 
5´-CCCAAGACTTAGTACCTGAA-3´ 
5´-TTGCCTCTTTCCTAGT٭ACTG-3´ 
57.3 
55.3 
55.3 
 
100 
P10-F 
P10-R 
P10m 
5´-CTCTGTTGCTGCAGATC-3´ 
5´-GCTGAGGTCACTCACCT-3´ 
5´-CTCTGTTGCTGCG٭GATC-3´ 
52.8 
55.2 
55.2 
 
140 
P11-F 
P11-R 
P11m 
5´-TGTCATCTCTCCTCCCTGCT-3´ 
5´-CAAGGGTTCAAAGACCCAAA-3´ 
5´-TGTCATCTCTCCTCCT٭TGCT-3´ 
59.4 
55.3 
57.3 
 
205 
(P: Primer, Pro: Promoter, F: Forward, R: Reverse, Pm: mutant Primer (Forward), Tm: Temperature Melting for primers) 
٭nucleotide replaced in forward primer 
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Table 2. Thermal cycle profile of the TP53 gene exons 
Time Extension Time Annealing Time Denaturation Exons 
1 min 72ºC 1 min 61.5ºC 1 min 96ºC Exon 2 
40 sec 72ºC 30 sec 58ºC 40 sec 96ºC 
30 sec 72ºC 30 sec 63ºC 30 sec 96ºC Exon 3 
50 sec 72ºC 40 sec 57ºC 1 min 96ºC Exon 4 
1 min 72ºC 1 min 62.5ºC 1 min 96ºC Exon 5 
40 sec 72ºC 30 sec 59ºC 40 sec 96ºC 
30 sec 72ºC 30 sec 61ºC 30 sec 96ºC Exon 6 
30 sec 72ºC 30 sec 57ºC 30 sec 96ºC Exon 7 
50 sec 72ºC 40 sec 54ºC 45 sec 96ºC Exon 8 
30 sec 72ºC 30 sec 58ºC 30 sec 96ºC Exon 9 
30 sec 72ºC 30 sec 55ºC 30 sec 96ºC Exon 10 
30 sec 72ºC 30 sec 62ºC 30 sec 96ºC Exon 11 
40 sec 72ºC 40 sec 59ºC 50 sec 96ºC Promoter 
 
SSCP and HA and DNA sequencing 
 In this study, due to financial constraints first for determination of polymorphisms single-
stranded conformation polymorphism (SSCP) were done on the samples and for detection of the 
difference between polymorphisms and mutations, RFLP using specific restriction enzymes were 
performed. For SSCP, a mixture of 5 μL of PCR product and 4 μL of denaturing buffer (90% 
formamide, 10 mM disodium EDTA, 1% xylene cyanol, and 1% bromophenol blue) was heated 
at 95°C for 15 minutes and then immediately placed on ice to prevent renaturation (KROTHAPALLI 
et al., 2012). 
 We used site-directed mutagenesis using primers, for the promoter and exons, changed in 
the 3´end of forward primers for one nucleotide (C to T or T to C) used in the healthy samples to 
create positive controls for SSCP. 
 For heteroduplex analysis (HA), 2.2 μL of PCR product from each sample was mixed with 
3.2 μL EDTA (5.0M), and heated at 95°C for 5 minutes and was slowly cooled using 60 cycles of 
30 sec to 37°C. Samples (5 μL) of each denatured PCR product were loaded on non-denaturing 
PAGE (8%) for 1 h at 50mA (Merk, Germany) (Table 3). The prepared SSCP product was mixed 
with HA product for each sample and was loaded on 8% PAGE. Bands were visualized by means 
of silver staining. Samples with mobility shifts were verified by a second independent PCR-
SSCP. 
 DNA sequencing of the PCR-amplified product with the motility shift on the gel and hose 
made positive controls was carried out bi-directionally on an ABI 3130 automated sequencer 
(Applied Biosystems) using the same primers. 
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Table 3. The optimized conditions for SSCP electrophoresis 
 
 
PCR-RFLP 
 In this study, we used PCR-RFLP in codon 248 with CGG sequence in exon 7 and codon 
282 in exon 8 with CGG sequence for which mutations have been frequently reported in gastric 
cancer. 
 The restriction enzyme HpaII (contain: a mixture of 10 μL of PCR product, 1 μL 
restriction enzyme, 2 μL buffer and 7 μL dH2O) digests (for 12 h at 37°C) within the sequence 
corresponding to the codon (CGG) at position 248 and codon (CGG) at position 282 to generate 
two visible fragments of 82 and 54 bp for codon 248 and fragments 140 and 100 bp for codon 282 
and leaves the mutant codons uncut. After electrophoresis in 8% poly acryl amide gel 
electrophoresis (PAGE) in 120 V for 1 h, it was visualized by means of silver (AgNO3) staining. 
 
 
RESULTS 
 SSCP analysis showed the differential motility of electrophoretic bands for the positive 
controls in the denatured region. This was shown for the positive controls of all exons. For the 
patients’ samples, no shifted band was evident except for three cases for exon 8 in which upon 
DNA sequencing no mutation was found (Figure 2). 
 PCR-RFLP results for codon 248 in exon 7 and codon 282 in exon 8 showed no mutation 
in the relative sequences, either. All the samples showed a single cut in exon 7 in 82 bp region 
and a single cut in exon 8 producing a 140 bp band (Figure 3). Thus, no mutation was found for 
any of the cancer samples (Figure 4). 
 
 
Other C)oTemperature ( Voltage (V) Milliampere 
(MA) 
Time (h) Gel concentration Exons 
— 20  280 32 5.30 8% Exon 2 
— 20  280 32 6.30 10% Exon 3 
urea10g 4 120 13 14 6% Exon 4 
urea10g 4 120 13 14 6% Exon 5 
— 20  280 32 7 12% Exon 6 
— 20  280 32 6 12% Exon 7 
— 20  280 32 5.30 8% Exon 8 
urea10g 20  280 32 3.50 6% Exon 9 
— 20  280 32 6 12% Exon 10 
— 20  280 32 7 12% Exon 11 
glycerol 80% 20  280 32 10 12% Promoter 
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A. 
B. 
Figure 2. The results of PCR-SSCP on promoter and exon 8 for example (m: Marker 100 bp and 1= negative 
control sample without denaturated PCR product) 
A: Promoter: 4= positive control, 2-3,5-9=Patient samples without the mutation. 
B: Exon 8: 6= positive control, 2-5,7-9=Patient samples without the mutation. 
 
 
Figure 3. The results of PCR-RFLP (m: marker 100 bp, (1) PCR product without restriction Enzyme, (A): 
codon 248 in exon 7: All the samples digested. 
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Figure 3. The results of PCR-RFLP (m: marker 100 bp, (1) PCR product without restriction Enzyme, (B): 
codon 284 in exon 8: All of samples digested. 
 
 
 
Figure 4. Sequencing of exon 8 of TP53 in some of the samples with positive SSCP results which showed no 
mutation 
 
DISCUSSION 
 The TP53 tumor suppressor gene is among the most frequently mutated genes in human 
cancer (HIYAMA et al., 1998). Many studies have presented clues of TP53 alterations, including 
both mutations and polymorphisms, as the most widespread genetic changes in human cancers, 
such as gastric cancer, cervical cancer, breast cancer, lung and colorectal cancer (OKI et al., 2005). 
Gastric adenocarcinomas have been shown to normally contain 18% to 58% TP53 mutation 
(MAESAWA et al., 1995; MONIG et al., 1997). Although p53 nuclear staining can be seen in both 
intestinal and diffuse type gastric tumors, it is more commonly observed in the intestinal type 
(FENOGLIO-PREISER et al., 2003). However, some investigators failed to find any difference 
between the two types (TANG et al., 2010). 
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 The existence and distribution of mutations in the gene differ among different cancers. For 
example, hepatocellular carcinoma is associated with codon 249 in exon 7 while no mutation in 
the codon has ever been reported for gastric cancer (MULLER and BORCHARD, 1996). While, 
researchers have shown an association of the TP53 codon 72 polymorphism with colorectal 
cancer in South West Iran (DOOSTI et al., 2011), a mutation in other codons might be more 
important in gastric carcinoma. The most common mutations reported thus far in TP53 in relation 
to gastric cancer include codons 175 and 248 which we studied by the sensitive RFLP technique 
and found no mutation (ARREGUI et al., 2002). The reported incidence of TP53 mutations in 
invasive carcinomas ranges from 0-79% (YAMADA et al., 1991). Meng and colleagues showed 
that mutation in exons 5-8 of the TP53 gene is 61% in mammary carcinoma (MENG et al., 1999). 
Codon 72 of the TP53 gene mutations in breast cancer in the Iranian patients and reported that 
polymorphism in this codon to be associated with breast cancer in these patients (DOOSTI et al., 
2011). In their study, 70 out of 135 (51.85%) patients with breast cancer were heterozygous 
(Arg/Pro), 52 (38.52%) were homozygous for arginine (Arg/Arg) and 13 (9.63%) samples 
homozygous for proline (Pro/Pro) (TESTINO et al., 2002). Studying 40 colorectal samples from 
Isfahan province, central Iran, 7 mutations in exon 6 of the gene were found (GOLMOHAMMADI 
and NIKBAKHT, 2006). The esophageal cancer study from north of Iran, a focal region of 
esophageal cancer, on 74 samples led to the finding of 54 (65%) positive samples for mutations in 
the gene (BIRAMIJAMAL et al., 2001). Geographic region and ethnicity can affect the mutation 
distributions of genes. This has been shown for TP53 mutations associated with gastric cancer. In 
Japan, for example, mutations of exon8 comprised 5.2% in a Japanese society while was obtained 
to be 28% in another population from Japan (MUNOZ-FONTELA et al., 2005). 
 CHEN et al. (2011) studied exons 5-8 of TP53 and reported 29.3% mutations in China. 
Shiao et al. (1994) studied in gastric cancer gene mutations and reported that the mutation in this 
gene was found in about 66% of the cases (SHIAO et al., 1994). In contrast, LUINETTI et al. (1998) 
showed that mutation in this gene in gastric cancer is about 26%. 
 UCHINO et al. (1993) showed 25% mutations in primary gastric cancer and 42% mutation 
in advanced gastric cancer. TOLBERT et al. (1999) observed mutations in 42% of the intestinal and 
21% of the peripheral gastric cancer. However, in 2005 40.6% mutation in intestinal and 8.2% in 
peripheral gastric cancer observed (OKI et al., 2005). Based on a study by YAMADA et al. (1991) 
on 19 primary gastric cancers from Japan, no TP53 mutation was reported. As mentioned above, 
there are many studies showing that mutations in the TP53 are abundant in various cancers in the 
world. However, in our study analyzing 38 samples of paraffin-embedded tissue in gastric cancer 
in a province of Iran (Chaharmahal Va Bakhtiari) we failed to find any mutation in TP53 by PCR-
SSCP techniques. Although we applied some modifications to the technique and used the 
simultaneous heteroduplex analysis, SSCP is not at all 100% sensitive and it is possible that some 
of the mutations might have been overlooked (WEGHORST et al., 1993). We confirmed our study 
by PCR-RFLP techniques in codons 248 and 282 on exons 7 and 8 that are two hot spots regions 
for TP53 in gastric cancer. Notably, all of the positive control samples in PCR-SSCP had shifted 
in gel electrophoresis. The restriction enzyme in PCR-RFLP cut all of the patient samples in 
codons 248 and 282 on exons 7 and 8.  
 In summary, in the present study the relation between gastric cancer and TP53 gene, no 
mutation was detected. This could be tightly linked to the ethnicity. Other genes in the same 
pathway or alternatively, other pathways might be involved in the carcinogenesis process. Further 
studies with larger sample size from the region may better clarify the idea.  
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Izvod 
Kancer želuca je na drugom mestu po smrtnosti u svetu, posle kancera pluća. Njegova etiologija 
je heterogena i genetski faktori uključujući protoonkogene i gene supresore tumora, uvek 
doprinosi razvoju kancera. Tumor supresor gen-TP53 ima veliku ulogu u genomskoj stabilnosti i 
reparaciji DNK. Cilj ovog istraživanja bio je da se odrede mutacije gena TP53 kod uzoraka 
kancera želuca u Iranskoj provinciji Chaharmahal Va Bakhtiari. U ovom laboratorijskom 
istraživanju, proučavani su promoter i egzoni TP53 genske mutacije kod 38 uzoraka kancera 
želuca. Ekstrakcija DNK je urađena prema standardnom fenol-hloroform protokolu. Mutacije 
gena TP53 određene su tehnikama PCR-SSCP i PCR-RFLP. Istraživanjem nisu otkrivene 
mutacije TP53 gena u promotoru i egzonu uzoraka kancera želuca. Iako su mutacije gena TP53 
najčešće i utvrđene kod oko 50% maligniteta, u ovom istraživanju nisu utvrđene mutacije. Razlog 
mogu biti mutacije u drugim srodnim genima ili epigenetski faktor. 
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